Tenon Medical Inc. (TNON) experienced a dramatic sell-off on Thursday, with shares plummeting 41.9% to close at $0.35, marking a new 52-week low. The decline occurred on record-breaking volume of approximately 31.75 million shares, more than 350 times the stock's typical daily average. The sharp drop came despite a broadly positive day for the broader market, as the Nasdaq Composite surged 1.9% and the Russell 2000 small-cap index added 2.1%.
Nasdaq Compliance Challenges
The timing of the sell-off is particularly critical for Tenon. The company is already under pressure from Nasdaq due to non-compliance with listing requirements. In May, Tenon received a notice from Nasdaq for failing to meet the $2.5 million minimum stockholders' equity requirement. As of March 31, the company's stockholders' equity stood at only $1.895 million. Tenon has until July 6 to submit a plan to regain compliance, and the stock's slide below $1 adds further urgency, as a sustained low price could trigger an additional delisting risk.
The market's closure on Friday for the Juneteenth holiday means investors have limited time to react before trading resumes on Monday. This compressed timeline amplifies the pressure on the company to address its capital structure issues.
Reverse Stock Split Proposal
In a preliminary proxy filing with the SEC, Tenon is seeking shareholder approval for a reverse stock split, with ratios ranging from 1-for-2 to 1-for-35. The move is intended to boost the share price artificially and help meet Nasdaq's minimum bid price requirement. However, a reverse split does not address the underlying equity deficiency or cash flow problems. Shareholders are scheduled to vote on the proposal at the company's virtual annual meeting on July 23.
Financial Struggles and Going-Concern Warning
Despite reporting strong revenue growth in the first quarter—up roughly 90% to $1.4 million and a gross margin improvement to 68.5%—Tenon's balance sheet remains precarious. The company reported $4.6 million in cash and equivalents as of March 31, but an accumulated deficit of $84.8 million. Tenon has not yet generated positive operating cash flow, and management has issued a going-concern warning, stating that current cash reserves are insufficient to cover obligations for the next 12 months.
Market Context
The sell-off in Tenon appears to be company-specific rather than sector-wide. Competitor SI-BONE (SIBN) finished the session up at $15.84, while Orthofix Medical (OFIX) rose to $9.45. The massive volume spike suggests speculative trading and potential forced selling, rather than a fundamental shift in the medical device industry.
Outlook and Risks
Looking ahead, Tenon faces significant hurdles. The reverse stock split, if approved, may provide temporary relief for the stock price but does not address the need for additional capital. The company may be forced to seek debt or equity financing, which could dilute existing shareholders. Furthermore, Nasdaq could reject Tenon's compliance plan if it deems the measures insufficient. The July 6 deadline looms, and the company's ability to secure a viable path forward remains uncertain.
